自免疫性肝炎重叠综合征:临床表现,治疗反应和疾病演变:三级中心的经验
Abduljaleel Al Alwan1,2,3, Ibrahim Altraif1,4, Hamdan Alghamdi1,2,3
1College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
概括
自免疫性肝炎 (AIH) 叠加综合征的治疗反应和缓解率与标准AIH相似. 没有复发的存活率各不相同,较高的初始得分预测了这些肝脏疾病的较差结果.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 自免疫性肝脏疾病是什么?
- 胆血管病变是一种胆血管病变.
背景情况:
- 自身免疫性肝炎 (AIH) 叠加综合征与AIH的特征以及原发性硬化胆炎 (PSC) 或原发性胆炎 (PBC) 的特征.
- 在阿拉伯人群中评估这些综合征对于理解其特定的临床特征和结果至关重要.
研究的目的:
- 评估阿拉伯人口中AIH重叠综合征的临床表现,治疗反应和疾病结果.
- 为了比较PBC/AIH和PSC/AIH重叠综合征与独立AIH的结果.
主要方法:
- 在沙特阿拉伯,从2001年到2024年对AIH重叠患者 (PBC/AIH,n=19;PSC/AIH,n=17) 和独立AIH患者 (n=93) 的回顾性审查.
- 利用PBC/AIH的巴黎标准和PSC/AIH的修订的国际自身免疫性肝炎组得分.
- 主要终点:疾病进展,肝移植或死亡率.
主要成果:
- AIH重叠综合征和独立AIH在相似的年龄被诊断出.
- 儿童-图尔科特-普格 (CTP) 和梅奥诊所的得分在PSC/AIH有所改善,但没有PBC/AIH重叠.
- 疾病进展,缓解率和无复发生存期 (RFS) 在PBC/AIH和PSC/AIH队列之间是可比的. 较高的初始梅奥和CTP得分预测了不良结果.
结论:
- AIH重叠综合征的治疗反应,缓解率和RFS与独立的AIH相似,尽管PBC/AIH和PSC/AIH之间的得分改善有所不同.
- 较高的初始疾病严重性得分 (Mayo,CTP) 与更差的预后有关.
- 建议对AIH重叠综合征患者进行进一步的长期随访研究.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
The Evidence for Evolution
48.3K
Genetic variations accumulating within populations over generations give rise to biological evolution. Evolutionary changes can result in the formation of novel varieties and entire new species. These changes are responsible for the diverse forms of life inhabiting the planet. The evidence for evolution suggests that all living organisms descended from common ancestors.
48.3K
Self-Presentation
323
Self-presentation is a fundamental aspect of social interaction, shaping both how others perceive individuals and how they view themselves. This dynamic process influences behaviors in various social settings, often leading people to adjust their appearance, speech, and demeanor to align with their desired identity. While self-presentation can be deliberate or unconscious, it plays a critical role in interpersonal relationships and self-perception.Forms of Self-PresentationSelf-presentation can...
323
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
247
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment
959
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
959


